Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
Journal
Clinical lymphoma, myeloma & leukemia
Journal Volume
22
Journal Issue
8
Pages
e751 - e761
Date Issued
2022-08
Author(s)
Sunami, Kazutaka
Ikeda, Takashi
Wang, Ming-Chung
Koh, Youngil
Min, Chang Ki
Yeh, Su-Peng
Matsumoto, Morio
Uchiyama, Michihiro
Iyama, Satoshi
Shimazaki, Chihiro
Lee, Jae Hoon
Kim, Kihyun
Kaneko, Hitomi
Kim, Jin Seok
Lin, Tung-Liang
Campana, Frank
Tada, Keisuke
Iida, Shinsuke
Suzuki, Kenshi
Abstract
In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the overall population of patients with relapsed/refractory multiple myeloma.
Subjects
Efficacy and safety; Far East; Isa-Pd; Japan; RRMM
Publisher
CIG MEDIA GROUP, LP
Type
journal article